Phenotyping of ABCA4 Retinopathy by Machine Learning Analysis of Full-Field Electroretinography.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
01 09 2022
Historique:
entrez: 30 9 2022
pubmed: 1 10 2022
medline: 5 10 2022
Statut: ppublish

Résumé

Biallelic pathogenic variants in ABCA4 are the commonest cause of monogenic retinal disease. The full-field electroretinogram (ERG) quantifies severity of retinal dysfunction. We explored application of machine learning in ERG interpretation and in genotype-phenotype correlations. International standard ERGs in 597 cases of ABCA4 retinopathy were classified into three functional phenotypes by human experts: macular dysfunction alone (group 1), or with additional generalized cone dysfunction (group 2), or both cone and rod dysfunction (group 3). Algorithms were developed for automatic selection and measurement of ERG components and for classification of ERG phenotype. Elastic-net regression was used to quantify severity of specific ABCA4 variants based on effect on retinal function. Of the cohort, 57.6%, 7.4%, and 35.0% fell into groups 1, 2, and 3 respectively. Compared with human experts, automated classification showed overall accuracy of 91.8% (SE, 0.169), and 96.7%, 39.3%, and 93.8% for groups 1, 2, and 3. When groups 2 and 3 were combined, the average holdout group accuracy was 93.6% (SE, 0.142). A regression model yielded phenotypic severity scores for the 47 commonest ABCA4 variants. This study quantifies prevalence of phenotypic groups based on retinal function in a uniquely large single-center cohort of patients with electrophysiologically characterized ABCA4 retinopathy and shows applicability of machine learning. Novel regression-based analyses of ABCA4 variant severity could identify individuals predisposed to severe disease. Machine learning can yield meaningful classifications of ERG data, and data-driven scoring of genetic variants can identify patients likely to benefit most from future therapies.

Identifiants

pubmed: 36178783
pii: 2783704
doi: 10.1167/tvst.11.9.34
pmc: PMC9527330
doi:

Substances chimiques

ABCA4 protein, human 0
ATP-Binding Cassette Transporters 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : Medical Research Council
ID : MR/S004041/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T019050/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206619/Z/17/Z
Pays : United Kingdom

Références

Exp Eye Res. 2009 Jun 15;89(1):16-24
pubmed: 19217903
Ophthalmology. 2017 Sep;124(9):1314-1331
pubmed: 28559085
Methods Mol Biol. 2008;444:161-7
pubmed: 18425479
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Acta Ophthalmol. 2017 May;95(3):240-246
pubmed: 27775217
J Med Genet. 2017 Jun;54(6):404-412
pubmed: 28446513
Ophthalmology. 2020 Oct;127(10):1384-1394
pubmed: 32423767
Hum Mol Genet. 2009 Mar 1;18(5):931-41
pubmed: 19074458
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):520
pubmed: 23329737
BMJ Open. 2014 Feb 12;4(2):e004015
pubmed: 24525390
Arch Ophthalmol. 2001 Mar;119(3):359-69
pubmed: 11231769
Invest Ophthalmol Vis Sci. 2016 Nov 01;57(14):5963-5973
pubmed: 27820952
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4249-4256
pubmed: 31618761
JCI Insight. 2022 Jan 25;7(2):
pubmed: 35076026
Am J Ophthalmol. 2021 May;225:95-107
pubmed: 33309813
Mol Vis. 2018 Jan 04;24:1-16
pubmed: 29386879
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4668-78
pubmed: 27583828
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751377
Am J Ophthalmol. 2013 Jun;155(6):1075-1088.e13
pubmed: 23499370
Ethn Dis. 2020 Apr 2;30(Suppl 1):217-228
pubmed: 32269464
Front Med (Lausanne). 2021 Dec 03;8:771713
pubmed: 34926514
Ophthalmology. 2016 Jun;123(6):1375-85
pubmed: 26976702
Doc Ophthalmol. 2018 Feb;136(1):1-26
pubmed: 29397523
Doc Ophthalmol. 2019 Oct;139(2):113-122
pubmed: 31187346

Auteurs

Sophie L Glinton (SL)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Antonio Calcagni (A)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Watjana Lilaonitkul (W)

Institute of Health Informatics, University College London, London, UK.
Health Data Research UK (HDRUK), London, UK.

Nikolas Pontikos (N)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Sandra Vermeirsch (S)

Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Gongyu Zhang (G)

Institute of Ophthalmology, University College London, London, UK.

Gavin Arno (G)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Siegfried K Wagner (SK)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Michel Michaelides (M)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Pearse A Keane (PA)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Andrew R Webster (AR)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Omar A Mahroo (OA)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Anthony G Robson (AG)

Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH